Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
Eur J Neurol. 2020 May;27(5):817-824. doi: 10.1111/ene.14159. Epub 2020 Feb 18.
Early neurological deterioration (END) occurs in 20%-30% of patients with lacunar stroke and challenges their clinical management. This retrospective cohort study analyzed clinical and neuroimaging risk factors predicting the occurrence of END, the functional outcome after END and potential benefit from dual antiplatelet therapy (DAPT) in patients with lacunar strokes.
Factors associated with END and benefit from DAPT were retrospectively analyzed in 308 patients with lacunar stroke symptoms and detected lacunar infarction by magnetic resonance imaging. END was defined by deterioration of ≥3 total National Institutes of Health Stroke Scale (NIHSS) points, ≥2 NIHSS points for limb paresis or documented deterioration within 5 days after admission. Patients were treated with DAPT according to in-house standards. The primary efficacy end-point for functional outcome was fulfilled if NIHSS at discharge improved after END at least to the score at admission.
Male gender [odds ratio (OR) 2.08; 95% confidence interval (CI) 1.09-4.00], higher age (OR = 1.65 per 10 years; 95% CI 1.18-2.31), motor paresis (OR = 18.89, 95% CI 4.66-76.57) and infarction of the internal capsule or basal ganglia (OR = 3.58, 95% CI 1.26-10.14) were associated with an increased risk for END. A larger diameter of infarction (OR = 0.85, 95% CI 0.76-0.95), more microangiopathic lesions (OR = 0.75, 95% CI 0.57-0.99) and pontine localization (OR = 0.29, 95% CI 0.12-0.65) were factors associated with unfavorable functional outcome after END occurred. Localization in the internal capsule or basal ganglia was identified as a significant predictive factor for a benefit from DAPT after END.
Identified clinical and neuroimaging factors predicting END occurrence, functional outcome after END and potential benefit from DAPT might improve the clinical management of patients with lacunar strokes.
20%-30%的腔隙性卒中患者会发生早期神经功能恶化(END),这对其临床管理构成了挑战。本回顾性队列研究分析了预测腔隙性卒中患者发生 END 的临床和神经影像学危险因素、END 后的功能结局以及双联抗血小板治疗(DAPT)的潜在获益。
本研究回顾性分析了 308 例磁共振成像显示腔隙性梗死且有腔隙性卒中症状的患者,这些患者的 END 与 DAPT 获益相关的因素。END 定义为 NIHSS 评分至少增加≥3 分,肢体无力的 NIHSS 评分至少增加≥2 分,或入院后 5 天内有记录的恶化。根据内部标准,对患者进行 DAPT 治疗。如果 END 后 NIHSS 评分至少恢复至入院时的评分,则出院时 NIHSS 评分改善,认为达到了主要的疗效终点。
男性(比值比[OR] 2.08;95%置信区间[CI] 1.09-4.00)、高龄(每增加 10 岁,OR=1.65;95% CI 1.18-2.31)、运动性无力(OR=18.89;95% CI 4.66-76.57)和内囊或基底节梗死(OR=3.58;95% CI 1.26-10.14)与 END 风险增加相关。梗死直径较大(OR=0.85;95% CI 0.76-0.95)、微出血性病变较多(OR=0.75;95% CI 0.57-0.99)和桥脑定位(OR=0.29;95% CI 0.12-0.65)与 END 后功能结局不良相关。内囊或基底节定位被确定为 END 后 DAPT 获益的显著预测因素。
预测 END 发生、END 后功能结局和 DAPT 潜在获益的临床和神经影像学因素,可能改善腔隙性卒中患者的临床管理。